SCHEMBL1904898

SCHEMBL1904898

CCOC(=O)C(C(=O)OCC)[C@H](c1ccccc1)C(C)[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 3/20 0.42
CYP2C19 P33261 2/20 0.42
PIN1 Q13526 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP3A4 P08684 2/20 0.40
GABRA1 P14867 2/20 0.40
GABRB2 P47870 2/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
LMNA P02545 1/20 0.40
CYP2C9 P11712 1/20 0.40
TP53 P04637 1/20 0.40
ABCB11 O95342 1/20 0.40
GABRA2 P47869 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11993134 1.00 MMP8 (0.44) MMP8SMN1; SMN2ALDH1A1CYP1A2CYP2C19
SCHEMBL1904268 1.00 MMP8 (0.44) MMP8SMN1; SMN2ALDH1A1CYP1A2CYP2C19
SCHEMBL11971723 1.00 MMP8 (0.44) MMP8SMN1; SMN2ALDH1A1CYP1A2CYP2C19
SCHEMBL1869157 0.83 MMP8 (0.56) MMP8SMN1; SMN2PIN1TP53MEN1
SCHEMBL18579300 0.82 TP53 (0.44) SMN1; SMN2ALDH1A1CYP1A2LMNATP53
SCHEMBL18579323 0.82 TP53 (0.44) SMN1; SMN2ALDH1A1CYP1A2LMNATP53
SCHEMBL12491230 0.82 CYP2D6 (0.44) ALDH1A1CYP2C19LMNACYP2C9KMT2A
SCHEMBL15203901 0.82 CYP2D6 (0.44) ALDH1A1CYP2C19LMNACYP2C9KMT2A
SCHEMBL578527 0.80 MMP8 (0.42) MMP8SMN1; SMN2ALDH1A1CYP1A2CYP2C19
SCHEMBL11993136 0.79 MMP8 (0.49) MMP8SMN1; SMN2PIN1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791273-B2 4R,5S-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity JSC GRINDEKS (LV) 2014-07-29 US claimed
EP-2496555-B1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY GRINDEKS JSC (LV) 2013-08-28 EP claimed
EP-2496555-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY Grindeks, A Joint Stock Company (LV) 2012-09-12 EP claimed
US-20120215010-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY JSC GRINDEKS (LV) 2012-08-23 US claimed
WO-2011054888-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY GRINDEKS, A JOINT STOCK COMPANY (LV) 2011-05-12 WO claimed
US-20140296317-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY JSC GRINDEKS (LV) 2014-10-02 US disclosed
US-8791273-B2 4R,5S-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity JSC GRINDEKS (LV) 2014-07-29 US disclosed
EP-2496555-B1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY GRINDEKS JSC (LV) 2013-08-28 EP disclosed
EP-2496555-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY Grindeks, A Joint Stock Company (LV) 2012-09-12 EP disclosed
US-20120215010-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY JSC GRINDEKS (LV) 2012-08-23 US disclosed
WO-2011054888-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY GRINDEKS, A JOINT STOCK COMPANY (LV) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296317-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY NAAA, NAT1, NAA15 MMP8 4476/4885SMN1; SMN2 1376/4885ALDH1A1 716/4885
US-20120215010-A1 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY NAAA, NAT1, NAA15 MMP8 4476/4885SMN1; SMN2 1376/4885ALDH1A1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.